Client News

Roquefort Therapeutics PLC – Director/PDMR Shareholding
Home / Client News / Roquefort Therapeutics PLC – Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Dr Darrin Disley, a Non-Executive Director, has purchased ordinary shares in the Company, as detailed below:


Number of Ordinary Shares

Average Price Paid Per Share

Total Consideration Paid


7.35 pence



Following the above purchase of shares, Dr Disley holds an interest in 1,495,901 Company ordinary shares, representing 1.16% of the Company’s issued share capital.



Director/PDMR Shareholding – 07:00:07 02 Aug 2023 – ROQ News article | London Stock Exchange


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This